Solventum (SOLV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is skewed to a revenue beat on Q2 given the well-telegraphed >$100M ERP pull-forward, but the real test is whether underlying organic growth (ex-pull-forward) is tracking toward the high end of the 2%–3% full-year guide, and whether adjusted EPS can sustain the upward trajectory that drove the Q1 beat.

Heading into Q2 2026, the bar for Solventum is deliberately distorted by a company-managed ERP cutover mitigation strategy: management guided to over $100M of distributor pre-orders pulled into Q2 from Q3, primarily in Infection Prevention & Surgical Solutions (IP&SS) and Dental, making reported revenue almost certain to come in well above a normalized run-rate. Consensus sits at ~$2.155B in revenue and ~$1.90 in adjusted EPS — both elevated relative to Q1 actuals ($2.007B / $1.48) and prior-year Q2 ($2.161B / $1.69), with the EPS comparison reflecting the P&F divestiture headwind on reported sales. Management’s posture has been consistently confident since the Q1 print: EPS guidance was moved to the high end of the $6.40–$6.60 range, full-year organic growth guidance was maintained at +2%–3%, and the CFO reiterated at the Jefferies Healthcare Conference in June that the company is “very confident” in achieving the full-year guide. Estimate revisions have been remarkably stable post-Q1 — Q2 EPS consensus moved from $1.88 on May 8 to $1.90 today, and full-year EPS from $6.55 to $6.55, suggesting the street has largely digested the pull-forward dynamic without meaningful upward or downward revision. The stock has rallied ~27% since the Q1 print (from $69 to ~$88), outperforming XLV meaningfully, driven almost entirely by multiple expansion rather than estimate revisions — suggesting the market is pricing in continued execution on the transformation story. The key wildcard is the magnitude of the ERP pull-forward relative to the $100M+ guide: if actual pre-orders came in materially above $100M, Q2 revenue could surprise significantly to the upside, but the Q3 reversal would be correspondingly larger — making the full-year guide the more important anchor than any single quarter’s print.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a high reported revenue bar (~$2.155B, +7% YoY organic implied by pull-forward) but the more meaningful signal will be the underlying organic growth rate ex-pull-forward and whether adjusted operating margin continues to expand. Adjusted EPS at $1.90 is the bigger swing factor — any gross margin upside (as in Q1) could drive a meaningful beat.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data; Solventum Q1 2026 Earnings Release (May 5, 2026). Segment consensus figures from Visible Alpha. Q2 organic growth consensus of ~7.0% reflects the >$100M ERP pull-forward; normalized underlying organic growth is estimated at ~3%–4% by management. MedSurg and Dental Q2 consensus elevated due to pull-forward impact on IP&SS and Dental segments specifically.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI #1: Total Revenue

Top KPI #2: Adjusted EPS (Diluted)

Pattern: SOLV has beaten consensus on both revenue and adjusted EPS in every quarter since its April 2024 spin-off, with EPS beats consistently running in the +5% to +19% range — a remarkably consistent track record that has set a high bar for the market’s expectations. The Q1 2026 EPS beat of +7.9% was driven by gross margin outperformance despite tariff headwinds, a pattern that could repeat if programmatic savings continue to outpace headwinds in Q2.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been incrementally tightened upward since the Q1 print — EPS moved to the high end of the $6.40–$6.60 range while revenue and FCF guidance were maintained. Management tone at the May BofA and June Jefferies conferences was consistently confident, with no new headwinds introduced.

Source: Solventum Q1 2026 Earnings Call Transcript (May 5, 2026); Solventum BofA Global Healthcare Conference Transcript (May 13, 2026); Solventum Jefferies Global Healthcare Conference Transcript (June 3, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 EPS consensus moved only +$0.02 and full-year EPS only +$0.01 over the past three months, suggesting the street has fully digested the pull-forward dynamic. The gap between consensus and guidance midpoint is narrow, leaving limited room for a guidance-driven re-rating unless management raises the full-year bar.

The near-zero estimate drift since the Q1 print reflects the market’s understanding that Q2 will be artificially elevated by the ERP pull-forward and Q3 will be correspondingly depressed — making the full-year guide the only meaningful anchor. If management raises the full-year EPS guide above $6.60 on the Q2 call, that would be the first meaningful positive catalyst for estimate revisions since the Q1 print.

Source: Visible Alpha Consensus and Actuals Data (revision history table, weekly frequency, May 8 – Aug 4, 2026).

5. Stock Performance

Key Takeaway: SOLV has rallied ~27% since the Q1 print vs. XLV +12% and SPY +7%, with the outperformance driven almost entirely by multiple expansion (EV/EBITDA expanded ~23% over 3 months) rather than estimate revisions — suggesting the market is re-rating the transformation story, but also that the stock has less cushion if Q2 disappoints on the underlying organic growth narrative.

SOLV vs. XLV (Health Care Select Sector SPDR ETF) vs. S&P 500 — Indexed Performance Since Q1 2026 Earnings (May 5, 2026 = 100)

Key Events Since Q1 Print:

• May 5, 2026: Q1 2026 earnings beat; EPS guidance raised to high end of $6.40–$6.60; share repurchase program initiated ($67M in Q1). Stock opened +2% day-after.
• May 13, 2026: BofA Global Healthcare Conference — management reiterated confidence in full-year guide; highlighted ERP pull-forward dynamics for Q2/Q3.
• Jun 3–4, 2026: Jefferies Global Healthcare Conference — CFO provided detailed color on capital allocation, tuck-in M&A framework, and accelerated share repurchases at lower stock prices. Stock rallied ~5% over the two-day period.
• Jun 5, 2026: 8-K filed (non-material administrative).
• Jul 15, 2026: SOLV announced Q2 2026 earnings date of August 5, 2026.
• Jul 20, 2026: 8-K filed — Neil Zieselman named Chief Accounting Officer (replacing Mary Wilcox).

Performance Decomposition: Over the 3-month period since Q1 earnings, SOLV’s +30% gain was driven by ~23% multiple expansion (EV/EBITDA from 7.48x to 9.21x) and only ~7% from estimate revisions — confirming the re-rating is sentiment/credibility driven rather than fundamental revision driven. The NTM P/E of 12.8x remains well below medtech peers, suggesting further re-rating potential if execution continues.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (Implied). Sector ETF: XLV (Health Care Select Sector SPDR ETF) — appropriate for SOLV’s diversified healthcare technology profile spanning medtech, dental, and health IT.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Trian activist escalation (late April 2026), which has added an external catalyst for accelerated portfolio action — particularly around HIS segment separation — that could be a significant overhang or catalyst depending on management’s response on the Q2 call.

• Late April 2026 — Trian Fund Management Activist Escalation: Nelson Peltz’s Trian (~5% owner) publicly escalated demands, calling for immediate HIS segment separation, overhead rightsizing, and improved capital allocation. Management has engaged but defended its transformation track record.
• Implication: Creates an external catalyst for accelerated portfolio action; any commentary on HIS strategic review or separation timeline on the Q2 call would be a significant market-moving event. The April 2026 expiration of spin-related tax constraints provides additional flexibility for portfolio actions.
• Jun 3, 2026 — Jefferies Global Healthcare Conference: CFO Wayde McMillan provided detailed capital allocation framework: tuck-in M&A up to $1B (preference for hundreds of millions or less), accelerated share repurchases at current lower stock prices, and three-category portfolio decision framework (strategic rationale, shareholder value unlock, RemainCo attractiveness).
• Implication: Signals management is actively deploying the $1B buyback authorization and is open to portfolio optimization — both supportive of the stock.
• May 13, 2026 — BofA Global Healthcare Conference: Management highlighted autonomous coding adoption accelerating “much quicker than anticipated,” international HIS expansion compressing from 3–5 years to 1–3 years per country, and Acera growing 40% in its first full quarter (ahead of internal expectations).
• Implication: Positive read-through for HIS organic growth trajectory and M&A integration capability.
• May 5, 2026 — Q1 2026 Earnings Beat & EPS Guidance Raise: Adjusted EPS of $1.48 (+7.9% vs. consensus); organic revenue growth of +2.1% (normalized ~4%); gross margin +80 bps YoY despite tariffs; EPS guidance raised to high end of $6.40–$6.60; $67M in share repurchases executed in Q1.
• Implication: Established a strong baseline for Q2; the gross margin outperformance despite tariff headwinds is the key positive signal to watch for in Q2.
• May 5, 2026 — ERP Pull-Forward Disclosure: Management guided to >$100M of distributor pre-orders pulled into Q2 from Q3 as a mitigation strategy for the US/Canada ERP cutover. Primarily impacts IP&SS and Dental segments.
• Implication: Q2 reported revenue will be materially elevated; Q3 will see a corresponding reversal. The full-year guide is the only meaningful anchor. Investors should focus on underlying organic growth ex-pull-forward.
• Jul 20, 2026 — Neil Zieselman Named Chief Accounting Officer: 8-K filed announcing Zieselman as new CAO, replacing Mary Wilcox.
• Implication: Routine leadership transition; no material impact on near-term financials.
• Ongoing — Transform for the Future Restructuring Program: Multi-year $500M savings program continues to provide “additional firepower” to offset tariff and inflation headwinds. SKU rationalization >50% complete, expected to finish by year-end.
• Implication: Programmatic savings are the primary driver of gross margin resilience; any update on savings realization pace would be a positive catalyst.
• Ongoing — TSA Exit Progress: >50% of transition service agreements exited as of Q1; on pace for >90% by year-end 2026. US/Canada ERP cutover (Q3) is the last large ERP event.
• Implication: Successful TSA exits free up management bandwidth and reduce separation costs, supporting the FCF normalization trajectory toward ~$1B by 2027–2028.

7. Peer Commentary Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for SOLV’s Q2 setup: hospital capital spending is stable-to-strong (Stryker, Baxter), dental consumables demand is durable (Henry Schein), and the broader healthcare market is improving (Thermo Fisher). The most direct read-through is from Align Technology’s Q2 2026 results, which confirm continued dental market volume growth but flag pricing pressure in digital equipment — relevant for SOLV Dental.

Methodology Note: Only forward-looking commentary about Q3 2026, H2 2026, or full-year 2026 from peers that reported Q2 2026 results is included below. Backward-looking commentary about peers’ own Q2 2026 results is excluded. Commentary from SOLV’s own post-Q1 conferences (BofA May 13, Jefferies Jun 3) is covered in Section 3 and 6 above.

7A. Dental Segment Read-Throughs

Align Technology (ALGN) — Q2 2026 Earnings (Reported July 29, 2026)

Relevance: ALGN is the global clear aligner market leader with significant overlap in orthodontics and digital dentistry — directly adjacent to SOLV’s Dental Solutions segment (restorative composites, orthodontic materials).

• Q3 2026 Outlook — Clear Aligner Volume Growth: ALGN guided Q3 2026 clear aligner volume up mid-single digits YoY, with full-year 2026 volume growth now expected at ~+6% YoY. This confirms continued underlying dental procedure demand, a positive read-through for SOLV Dental’s volume environment.
• Q3 2026 Outlook — Scanner/Equipment Pricing Pressure: ALGN guided Q3 Systems & Services revenue down sequentially and YoY, driven by a strategic mix shift toward lower-priced scanners and flexible acquisition models (leasing, rental). This signals ongoing pricing pressure in dental capital equipment — a cautionary read-through for any SOLV Dental capital equipment exposure.
• H2 2026 — North America Retail Softness: ALGN noted North America remained “relatively stable” but flagged softer retail demand as a top priority to address. DSO and orthodontic channels remain strong. This bifurcation is relevant for SOLV Dental’s channel mix.
• UK VAT Ruling (Effective Sep 7, 2026): UK Upper Tribunal ruled clear aligners do not qualify as VAT-exempt dental prostheses; 20% VAT applies from September 7, 2026. ALGN states this is a pass-through to providers with no ASP impact, but could dampen UK dental demand broadly — a minor read-through for SOLV Dental’s UK exposure.
• FY 2026 Non-GAAP Operating Margin: ALGN reiterated ~23% non-GAAP operating margin for FY 2026 (+100 bps YoY), with at least +100 bps targeted for FY 2027 as well — signaling the dental sector is capable of margin expansion despite macro headwinds.

Limitations: ALGN’s business is heavily weighted toward clear aligners and intraoral scanners, while SOLV Dental is primarily restorative composites and orthodontic materials. ALGN’s scanner revenue headwind from the mix shift to lower-priced models is a company-specific strategic choice, not a market-wide signal. ALGN’s restructuring charges and strategic review are company-specific.

Henry Schein (HSIC) — Q2 2026 Earnings (Reported August 4, 2026)

Relevance: HSIC is the largest dental products distributor in the US, serving the same dental practice and DSO customer base that purchases SOLV Dental’s restorative composites and orthodontic materials. HSIC’s commentary on dental consumables demand and channel dynamics is the most direct read-through for SOLV Dental.

• H2 2026 Dental Consumables Outlook: HSIC expects “similar range of growth” in US dental consumables in H2 2026 as H1, despite tougher comps. This is driven by successful conversion of episodic buyers to active customers and strong DSO channel momentum.
• Read-through for SOLV Dental: Stable-to-growing dental consumables demand is a direct positive for SOLV’s restorative composites and orthodontic materials volumes in Q2 and H2 2026.
• Dental Market Resilience: HSIC CEO stated markets are “stable and durable” with “good underlying fundamentals” and “not seeing a significant impact on patient volumes resulting from higher oil prices.”
• Read-through for SOLV: Dental patient volumes are holding up despite macro headwinds — supportive of SOLV Dental’s organic growth trajectory.
• DSO Segment Structural Tailwind: HSIC highlighted DSOs growing faster than the broader dental market as a structural advantage. SOLV Dental’s exposure to the DSO channel (if any) would benefit from this consolidation trend.
• Digital Equipment Pricing Pressure: HSIC noted scanner demand is shifting “towards the lower price entries in the market,” consistent with ALGN’s commentary. This confirms a market-wide trend toward lower-priced dental capital equipment.
• FY 2026 Guidance Raised: HSIC raised FY 2026 total sales growth guidance to 4.5%–5.5% (from 3%–5%) and non-GAAP EPS to $5.29–$5.39 (from $5.23–$5.37), reflecting stronger underlying sales performance.
• Read-through for SOLV: A dental distributor raising guidance is a positive macro signal for the dental supply chain broadly.

Limitations: HSIC’s outperformance is partly driven by company-specific initiatives (own brand growth at 2x market rate, DSO market share gains, value creation program). HSIC’s market share gains imply the underlying market may be growing more slowly than HSIC’s reported figures. HSIC does not provide direct commentary on dental materials pricing (composites, orthodontic materials) specifically.

7B. MedSurg / Hospital Environment Read-Throughs

Stryker (SYK) — Q2 2026 Earnings (Reported July 30, 2026)

Relevance: SYK is a leading medtech company with significant hospital capital equipment and consumables exposure, overlapping with SOLV’s MedSurg segment (infection prevention, wound care). SYK’s commentary on hospital capital spending and procedure volumes is a key read-through for SOLV MedSurg.

• Hospital Capital Environment — H2 2026: SYK expects “continued strength in the hospital capital environment through the remainder of the year” with an “elevated backlog” and “zero cancellations.”
• Read-through for SOLV MedSurg: Strong hospital capital spending is a positive backdrop for SOLV’s infection prevention and wound care capital equipment and consumables.
• US Procedural Volumes — Stable: SYK noted the “US procedural environment remained stable” with “no meaningful changes in volume trends” for high-acuity, medically necessary procedures. Demand for joint replacement is “unabated.”
• Read-through for SOLV MedSurg: Stable procedure volumes support SOLV’s wound care and infection prevention consumables demand.
• ASC Shift Continuing: SYK noted hip/knee procedures now ~20% in ASCs (up from 5% pre-COVID), a steady structural shift.
• Read-through for SOLV: SOLV’s infection prevention and wound care products are used across both hospital and ASC settings; the ASC shift is a potential volume tailwind.
• Modest Positive Pricing: SYK’s full-year guidance reflects “modestly positive pricing impact” — consistent with SOLV’s own normalized pricing range of +1% to -1%.
• Europe Slight Slowdown: SYK noted a “slight slowdown in Europe related to procedures” — a minor cautionary signal for SOLV’s international MedSurg exposure.

Limitations: SYK’s Q2 and H2 outlook is heavily influenced by its recovery from a Q1 cybersecurity incident and a peripheral vascular supply disruption — both company-specific events. SYK’s portfolio is weighted toward orthopedics and neurotechnology, not wound care or infection prevention consumables specifically. Tariff refunds boosted SYK’s Q2 EPS — a non-recurring item not applicable to SOLV.

Baxter International (BAX) — Q2 2026 Earnings (Reported July 30, 2026)

Relevance: BAX is a diversified medical products company with hospital consumables and IV solutions exposure, overlapping with SOLV’s MedSurg infection prevention and surgical solutions segment. BAX’s commentary on hospital capital spending and supply chain is a relevant read-through.

• Hospital Capital Spending — No Change: BAX stated “to date, in the US, we have not observed any change in hospital capital spending, and our order book continues to reflect solid demand.”
• Read-through for SOLV MedSurg: Consistent with SYK’s commentary — hospital budgets remain intact, a positive backdrop for SOLV’s capital-sensitive MedSurg products.
• Steady Demand Across End Markets: BAX noted “steady demand across our end markets” and “steady procedure volumes” in Advanced Surgery, with “strong performance in IV solutions.”
• Read-through for SOLV: Stable hospital procedure volumes and consumables demand are broadly supportive of SOLV’s MedSurg segment.
• Supply Chain Manageable: BAX noted supply chain pressures are “manageable and within guidance,” and oil price impacts have been “offset.”
• Read-through for SOLV: Consistent with SOLV’s own commentary that oil price impacts are deferred ~3 months via fixed contracts and are not expected to be material in 2026.
• FY 2026 Organic Growth Raised to +2%–3%: BAX raised full-year organic sales growth guidance, reflecting strong H1 and confidence in H2.
• Read-through for SOLV: A peer raising guidance in the same macro environment is a positive signal for SOLV’s ability to maintain its own full-year guide.

Limitations: BAX’s Q2 EPS beat was significantly boosted by a one-time $75M tariff refund ($0.11/share) — not applicable to SOLV. BAX is in an early-stage turnaround with company-specific issues (Novum LVP shipment hold, injectable supply constraints) that are not relevant to SOLV. BAX has no dental or HIS exposure.

Thermo Fisher Scientific (TMO) — Q2 2026 Earnings (Reported July 23, 2026)

Relevance: TMO is a broad life sciences and healthcare company. Its commentary on the overall healthcare market environment and supply chain is a general read-through for SOLV, though the overlap is limited given TMO’s focus on pharma/biotech rather than hospital consumables or dental.

• Broad Healthcare Market Strengthening: TMO noted “customer activity across our end markets continued to strengthen” and raised full-year organic revenue growth guidance to ~+4% (upper end of 3%–4% range).
• Read-through for SOLV: A broad-based improvement in healthcare end market demand is a positive macro backdrop for SOLV’s diversified portfolio.
• Academic & Government Markets Stabilizing: TMO noted academic and government markets “returned to growth” in Q2, with US “slightly positive.”
• Read-through for SOLV HIS: Stabilizing government/academic healthcare spending is a minor positive for SOLV’s HIS segment, which serves government-adjacent hospital systems.
• Tariff Navigation: TMO noted large pharma customers are “navigating tariffs successfully” — consistent with SOLV’s own commentary that tariff headwinds are manageable within guidance.

Limitations: TMO’s growth is primarily driven by pharma/biotech, bioproduction, and clinical research — segments with minimal overlap with SOLV’s hospital consumables, dental, or HIS businesses. TMO’s acquisition contributions ($1.6B revenue) and microbiology divestiture are company-specific. TMO provides no commentary on dental distribution, hospital budgets, or RCM software.

7C. Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells since the Q1 print. All transactions since May 5, 2026 are routine RSU vesting events (code M = exercise/conversion) with associated tax withholding dispositions (code F) — standard compensation plan mechanics with no directional signal. The absence of any open-market purchases or discretionary sales is neutral.

No open-market purchases (code P) or discretionary sales (code S) were filed in the period since the Q1 2026 earnings print. All transactions are routine compensation-related events (RSU vesting and associated tax withholding). The absence of any open-market buying by insiders at current price levels (~$85–$88) is neutral — neither a positive nor negative signal given the stock’s +27% rally since the Q1 print.

Source: SEC Form 4 Filings Database (Insider Transaction Data).

9. Key Risks

Downside Risks

• ERP Pull-Forward Reversal Larger Than Expected (Q3 Risk): If the Q2 pull-forward exceeded $100M, the Q3 reversal will be correspondingly larger, potentially causing Q3 reported revenue to miss consensus materially. Management has explicitly warned against modeling Q2 with precision.
• Tariff Headwinds Worse Than Guided: SOLV’s $100M–$120M tariff headwind estimate is built into guidance, but management acknowledged that if tariffs prove worse than assumed, it would be a headwind to the guide. Any escalation in US-China trade tensions could disproportionately impact SOLV’s MedSurg and Dental supply chains.
• Gross Margin Compression: Management guided gross margins for remaining quarters at ~56% (slightly below Q1’s 56.4%). If programmatic savings from Transform for the Future slow or tariff pass-through accelerates, gross margin could disappoint — the primary driver of Q1’s EPS beat.
• HIS Competitive Pressure (CPS/Speech): Management explicitly flagged price erosion in Clinician Productivity Solutions (speech tools) due to Microsoft/Nuance DAX and Epic’s ambient documentation rollout. If CPS declines accelerate beyond the “expected double-digit decline” guided in Q1, HIS organic growth could disappoint.
• Trian Activist Overhang: If Trian escalates further (proxy fight, public letter) without a constructive management response on the Q2 call, the stock could face sentiment pressure. Conversely, any announcement of HIS strategic review or separation could be a significant positive catalyst.
• FCF Normalization Slower Than Expected: Q1 FCF of ($273M) was well below the ~$200M full-year guide, requiring a significant H2 ramp. If separation costs or working capital headwinds persist longer than expected, FCF could miss the full-year target.

Upside Risks

• ERP Pull-Forward Larger Than $100M: If distributors pre-ordered more than the guided $100M+, Q2 reported revenue could significantly exceed consensus — though this would be a timing benefit, not a fundamental beat.
• Gross Margin Upside (Repeat of Q1): If programmatic savings from Transform for the Future continue to outpace tariff and inflation headwinds, gross margin could again exceed the ~56% guide — the most direct path to an EPS beat.
• Full-Year EPS Guidance Raise: If Q2 underlying performance is strong enough, management could raise the full-year EPS guide above the current $6.60 high end — the first meaningful positive catalyst for estimate revisions since Q1.
• Tariff Favorability: Management explicitly flagged that if tariffs prove more favorable than the $100M–$120M assumption, it would be an upside to guidance. Any tariff refunds (as received by SYK and BAX peers) would be incremental.
• HIS Autonomous Coding Acceleration: Management stated close to 50% of customers could migrate to autonomous coding during the strategic plan period. Any acceleration in adoption velocity would be a high-margin revenue upside for the HIS segment.
• Portfolio Action Announcement: Any announcement of HIS strategic review, tuck-in acquisition, or accelerated share repurchase program execution would be a positive catalyst, particularly given Trian’s pressure and the April 2026 expiration of spin-related tax constraints.